All manuscripts
Publications CAR T Cells DC Cells TIL Cells

Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy

Published Journal The Journal of Immunology

Share
27 pages Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy

Overview

This review groups autologous cancer cell therapies into four classes and sets out the engineering hurdles of each. Long manufacturing times, specialized expansion processes and quality control come up across all of them.

What this paper found

Autologous cell therapies for cancer fall into four classes: CAR T cells, tumor-infiltrating lymphocytes, dendritic cell vaccines and whole tumor cell vaccines. Each class faces distinct engineering hurdles. CAR T cells need efficient, multiplexed gene editing and more consistent products, while TIL therapy needs simpler, faster manufacturing and less exhaustion. DC vaccines require better cell sources, antigen loading and lymph node trafficking, and tumor cell vaccines need wider patient eligibility and consistent genetic modification. Across all four, the review identifies long manufacturing times, specialized expansion processes, quality control, trafficking, and toxicity from cytokines or lymphodepletion as shared challenges, and it describes engineering solutions for each.

Note: This is a narrative review of published work; it reports no new experiments.

Regardless of cell type for each therapy, there are innate manufacturing challenges in deriving a personalized therapeutic from patient cells. — Colleen R Foley, Sheridan L Swan, Melody A Swartz, The Journal of Immunology

Study details

Authors
Colleen R Foley, Sheridan L Swan, Melody A Swartz
Institution
Pritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois · Committee on Immunology, University of Chicago, Chicago, Illinois · Ben May Department of Cancer Research, University of Chicago, Chicago, Illinois
Journal
The Journal of Immunology
Year
2024
PMID / PMC
PMID: 38166251 · PMC
Cell type(s)
CAR T Cells, DC Cells, TIL Cells
Application area
Hematologic malignancy · Solid tumor

Explore related

Full citation

Foley CR, Swan SL, Swartz MA. Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. J Immunol. 2024;212(2):188-198.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →